Supplementary figure 1. Tumor specimen and PDO HG-26 prior to rapid drug screening



Supplementary figure 2. OC PDOs retained genomic features of the original tumor lesion (SNVs)



Supplementary figure 3. OC organoids retained genomic features of the original tumor lesion (CNVs)



Supplementary figure 4. Correlation of OC PDO drug response with specific measures of clinical response



Supplementary figure 5. Reproducibility between PDO technical replicates in terms of drug response



Supplementary figure 6. Likelihood of HR-deficiency based on HR-classifier CHORD



Supplementary figure 7. Reproducibility between biological replicates in terms of drug response



Supplementary figure 8. Drugs that elicit similar drug responses in related OC PDOs



Legend

- Unrelated organoids
- Plasma concentration (Css/Cmax)

Multiple locations:
- END−1
- HGS−13
- HGS−3
- LGS−2
- LGS−3
- LGS−5
- MC−3

Multiple timepoints:
- HGS−1

Supplementary figure 9. Confirmation of KRAS-mutation status by Sanger sequencing in PDOs MC-3



Supplementary figure 10. OC PDOs exhibit a certain degree of genome-wide heteroeneity at both the SNV and CVA level